title: Are topical keratolytic agents needed in the treatment of scalp psoriasis?
abstract: BACKGROUND
  Topical corticosteroids are the primary treatment for scalp psoriasis. Keratolytic agents are promoted as adjunctive treatments. However, complex treatment regimens may result in poor adherence and outcomes.
  
  
  OBJECTIVE
  To evaluate the evidence for the need for use of topical keratolytic agents as opposed to topical corticosteroid monotherapy in the treatment of scalp psoriasis.
  
  
  METHODS
  A review of the literature was performed seeking clinical trials using topical keratolytics, topical corticosteroids or the combination for treatment of scalp psoriasis.
  
  
  RESULTS
  Complete clearance of scalp psoriasis can be achieved in 10-78% of patients using topical corticosteroids alone, in 3% of patients using topical keratolytics alone, and in up to 84% using a combination of topical keratolytics and topical steroids. Clinical trials comparing the combination of keratolytics and topical corticosteroids versus topical corticosteroids alone found marginally more efficacy using combination regimens.
  
  
  CONCLUSIONS
  We could not find any long term study evaluating the efficacy of combination therapy in scalp psoriasis and its effect on the patients' adherence.
  
  
  CONCLUSIONS
  High potency topical corticosteroids are usually effective in treating scalp psoriasis in clinical trials. Poor efficacy in clinical practice may be owing to poor adherence to the treatment regimen. Using a keratolytic agent in conjunction with a topical corticosteroid may provide marginal additional benefit in clinical trials, but that benefit is likely outweighed by the downside of complicating treatment and reducing adherence in the clinical setting, unless a single product containing both medications were used.
authors.affiliation: Wake Forest School of Medicine.
authors.forename: Divya
authors.initials: D
authors.lastname: Shokeen
authors.forename: Jenna L
authors.initials: JL
authors.lastname: O'Neill
authors.forename: Arash
authors.initials: A
authors.lastname: Taheri
authors.forename: Scott R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D000279:Administration, Cutaneous; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D055118:Medication Adherence; D011565:Psoriasis / Q000188:drug therapy*; D012536:Scalp Dermatoses / Q000188:drug therapy*; D016896:Treatment Outcome; D019564:Unnecessary Procedures
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D007641:Keratolytic Agents